Kate N Wang1,2, J Simon Bell3,4,5,6, Edwin C K Tan3,7,8, Julia F M Gilmartin-Thomas5, Michael J Dooley3,9,5, Jenni Ilomäki3,5. 1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (Parkville Campus), 407 Royal Parade, Parkville, VIC, 3052, Australia. kate.wang@monash.edu. 2. Pharmacy Department, Alfred Health, Melbourne, VIC, Australia. kate.wang@monash.edu. 3. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (Parkville Campus), 407 Royal Parade, Parkville, VIC, 3052, Australia. 4. NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, NSW, Australia. 5. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. 6. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia. 7. Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. 8. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. 9. Pharmacy Department, Alfred Health, Melbourne, VIC, Australia.
Abstract
OBJECTIVE: Our objective was to investigate associations between proton pump inhibitor (PPIs) use and infection-related hospitalizations among residents of long-term care facilities (LTCFs). METHODS: This was a case-control study of residents aged ≥ 65 years admitted to hospital between July 2013 and June 2015. Residents admitted for infections (cases) and falls or fall-related injuries (controls) were matched for age (± 2 years), sex, and index date of admission (± 6 months). Conditional logistic regression was used to estimate crude and adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for associations between PPI use and infection-related hospitalizations. Analyses were adjusted for age, sex, polypharmacy, diabetes, heart failure, chronic obstructive pulmonary disease, myocardial infarction, cerebrovascular accident, and concomitant use of cancer and immunosuppressant medications. Subgroup analyses were performed for high- and low/moderate-intensity PPIs and for respiratory and non-respiratory infections. Logistic regression was used to compare the odds of infection-related hospitalizations among users of high- and low/moderate-intensity PPIs. RESULTS: Overall, 181 cases were matched to 354 controls. Preadmission PPI use was associated with infection-related hospitalizations (aOR 1.66; 95% CI 1.11-2.48). In subgroup analyses, the association was apparent only for respiratory infections (aOR 2.26; 95% CI 1.37-3.73) and high-intensity PPIs (aOR 1.93; 95% CI 1.23-3.04). However, the risk of infection-related hospitalization was not significantly higher among users of high- versus low/moderate-intensity PPIs (aOR 1.25; 95% CI 0.74-2.13). CONCLUSION: Residents who use PPIs may be at increased risk of infection-related hospitalizations, particularly respiratory infections. Study findings provide further support for initiatives to minimize unnecessary PPI use in the LTCF setting.
OBJECTIVE: Our objective was to investigate associations between proton pump inhibitor (PPIs) use and infection-related hospitalizations among residents of long-term care facilities (LTCFs). METHODS: This was a case-control study of residents aged ≥ 65 years admitted to hospital between July 2013 and June 2015. Residents admitted for infections (cases) and falls or fall-related injuries (controls) were matched for age (± 2 years), sex, and index date of admission (± 6 months). Conditional logistic regression was used to estimate crude and adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for associations between PPI use and infection-related hospitalizations. Analyses were adjusted for age, sex, polypharmacy, diabetes, heart failure, chronic obstructive pulmonary disease, myocardial infarction, cerebrovascular accident, and concomitant use of cancer and immunosuppressant medications. Subgroup analyses were performed for high- and low/moderate-intensity PPIs and for respiratory and non-respiratory infections. Logistic regression was used to compare the odds of infection-related hospitalizations among users of high- and low/moderate-intensity PPIs. RESULTS: Overall, 181 cases were matched to 354 controls. Preadmission PPI use was associated with infection-related hospitalizations (aOR 1.66; 95% CI 1.11-2.48). In subgroup analyses, the association was apparent only for respiratory infections (aOR 2.26; 95% CI 1.37-3.73) and high-intensity PPIs (aOR 1.93; 95% CI 1.23-3.04). However, the risk of infection-related hospitalization was not significantly higher among users of high- versus low/moderate-intensity PPIs (aOR 1.25; 95% CI 0.74-2.13). CONCLUSION: Residents who use PPIs may be at increased risk of infection-related hospitalizations, particularly respiratory infections. Study findings provide further support for initiatives to minimize unnecessary PPI use in the LTCF setting.
Authors: Kevin L Sloan; Anne E Sales; Chuan-Fen Liu; Paul Fishman; Paul Nichol; Norman T Suzuki; Nancy D Sharp Journal: Med Care Date: 2003-06 Impact factor: 2.983
Authors: Natali Jokanovic; Edwin C K Tan; Michael J Dooley; Carl M Kirkpatrick; J Simon Bell Journal: J Am Med Dir Assoc Date: 2015-04-11 Impact factor: 4.669
Authors: Robert J F Laheij; Miriam C J M Sturkenboom; Robert-Jan Hassing; Jeanne Dieleman; Bruno H C Stricker; Jan B M J Jansen Journal: JAMA Date: 2004-10-27 Impact factor: 56.272
Authors: Lorien S Dalrymple; Yi Mu; Danh V Nguyen; Patrick S Romano; Glenn M Chertow; Barbara Grimes; George A Kaysen; Kirsten L Johansen Journal: Clin J Am Soc Nephrol Date: 2015-11-13 Impact factor: 8.237
Authors: Anca Trifan; Carol Stanciu; Irina Girleanu; Oana Cristina Stoica; Ana Maria Singeap; Roxana Maxim; Stefan Andrei Chiriac; Alin Ciobica; Lucian Boiculese Journal: World J Gastroenterol Date: 2017-09-21 Impact factor: 5.742
Authors: Natali Jokanovic; Kris M Jamsen; Edwin C K Tan; Michael J Dooley; Carl M Kirkpatrick; J Simon Bell Journal: Drugs Real World Outcomes Date: 2017-12
Authors: Louise Christensen; J Rick Turner; Gregory M Peterson; Mark Naunton; Jackson Thomas; Kwang Choon Yee; Sam Kosari Journal: J Clin Med Date: 2019-11-04 Impact factor: 4.241